热门资讯> 正文
Avita Medical在REcell GO获得CE认证后股价上涨10%
2025-09-15 17:30
- Avita Medical (NASDAQ:RCEL) has received the CE Mark under the European Union Medical Device Regulation (EU MDR) for RECELL GO, sending shares up nearly 10% in premarket trading on Monday.
- “CE Mark for RECELL GO is an important milestone for Avita Medical and for patients,” said CEO Jim Corbett. “It enables us to bring this option to burn centers and clinicians in Europe to support their treatment of patients with acute wound injuries.”
- RECELL GO is a point-of-care device used by healthcare professionals to prepare a suspension of a patient’s own skin cells from a small sample of healthy skin. The cells are applied to promote healing in burns and traumatic or surgical wounds. RECELL GO builds on the RECELL System already in use across Europe.
More on AVITA Medical
- AVITA Medical, Inc. (RCEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
- AVITA Medical: Green Shoots Peaking Out From Hard Clay
- AVITA Medical, Inc. 2025 Q2 - Results - Earnings Call Presentation
- Avita projects $76M–$81M 2025 revenue with rebound expected as claims backlog eases
- AVITA Medical GAAP EPS of -$0.38 misses by $0.12, revenue of $18.42M misses by $4.02M
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
